We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Patent Trial and Appeal Board sided with Biogen in Mylan’s patent challenge over Biogen’s multiple sclerosis drug Tecfidera (dimethyl fumarate). Read More
The FDA revoked orphan drug status for Indivior’s overdose-treatment Sublocade in November 2019, admitting that it made a mistake in granting the designation. Read More
In his State of the Union address last night, President Trump called on Congress to pass legislation to curb the nation’s high drug prices, saying he would sign a bipartisan bill into law if it reached the Oval Office. He did not mention insulin pricing as expected. Read More
A U.S. court has ruled in favor of the FDA in a case filed by Vanda Pharmaceuticals alleging the agency didn’t provide an adequate scientific reason for a partial clinical hold issued in December 2018 for the company’s long-term study of tradipitant. Read More
In the wake of declaring the coronavirus a global emergency, the World Health Organization (WHO) has issued a new procedure for drugmakers that wish to submit unapproved drug products for public health crises. Read More
The vendor was charged with receiving $1 million from an unnamed opioid drugmaker to create an alert aimed at pushing doctors to prescribe more extended-release opioids. Read More
Sponsors of biologics and biosimilars should carefully consider how they present safety and efficacy information in their promotional materials, the FDA said in a draft guidance released yesterday. Read More